Page last updated: 2024-11-04

tebuthiuron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5383
CHEMBL ID1457493
CHEBI ID81745
SCHEMBL ID66366
MeSH IDM0055755

Synonyms (104)

Synonym
BRD-K34820100-001-02-1
tebuthiuron
urea, n-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-n,n'-dimethyl-
KBIO1_001466
DIVK1C_006522
SPECTRUM_001825
BSPBIO_002345
SPECTRUM5_001958
NCGC00023459-03
NCGC00023459-02
NCGC00023459-04
n-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)-n,n'-dimethylurea
urea, 2-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethyl-
tebuthiuron [ansi:bsi:iso]
tebulan
el-103
urea, 1-(5-(t-butyl)-1,3,4-thiadiazol-2-yl)-1,3-dimethyl-
sha 105501
prefmid
1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-3-dimethylharnstoff [german]
caswell no. 366aa
1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea
brn 0527479
einecs 251-793-7
graslan
perflan
tiurolan
spike
graslan 250 brush bullets
urea, n-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)-n,n'-dimethyl-
brush bullet
brulan
n-(5-(1,1-dimethylaethyl)-1,3,4-thiadiazol-2-yl)-n,n'-dimethylharnstoff [german]
epa pesticide chemical code 105501
spike 80w
hsdb 6863
smr000036753
MLS000079345
KBIOGR_001065
KBIO3_001845
KBIO2_002327
KBIOSS_002330
KBIO2_007463
KBIO2_004895
SPECTRUM3_000823
SPBIO_001782
SPECPLUS_000426
SPECTRUM4_000663
SPECTRUM2_001881
SPECTRUM330031
34014-18-1
n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-n,n'-dimethylurea
NCGC00020997-01
NCGC00023459-05
AKOS005467953
NCGC00020997-08
NCGC00020997-03
NCGC00020997-02
NCGC00020997-05
NCGC00020997-07
NCGC00020997-06
NCGC00020997-04
STK537090
C18436
tox21_300802
dtxcid704316
cas-34014-18-1
dtxsid3024316 ,
NCGC00254706-01
tox21_201451
NCGC00259002-01
chebi:81745 ,
CHEMBL1457493
1-(5-(tert-butyl)-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea
A822041
CCG-39419
HMS2451L04
n-[5-(tert-butyl)(1,3,4-thiadiazol-2-yl)]-n-methyl(methylamino)carboxamide
1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-3-dimethylharnstoff
n-(5-(1,1-dimethylaethyl)-1,3,4-thiadiazol-2-yl)-n,n'-dimethylharnstoff
e5ox6gm11e ,
unii-e5ox6gm11e
FT-0630577
tebuthiuron [mi]
tebuthiuron [hsdb]
tebuthiuron [iso]
SCHEMBL66366
T3647
n-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-nn'-dimethylurea
urea, 1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethyl-
perfmid
bushwacker
preflan
HBPDKDSFLXWOAE-UHFFFAOYSA-N
el 103
tebuthiuron, pestanal(r), analytical standard
tebuthiuron 10 microg/ml in acetonitrile
J-019419
mfcd00078732
1-[5-(tert-butyl)-1,3,4-thiadiazol-2-yl]-1,3-dimethylurea
Q125986
T72327
BS-44188
CS-0320310

Research Excerpts

Overview

Tebuthiuron (TBU) is a phenylurea herbicide that is extensively used in sugarcane fields.

ExcerptReferenceRelevance
"Tebuthiuron (TBU) is a phenylurea herbicide that is extensively used in sugarcane fields. "( Influence of temperature on biomarker responses and histology of the liver of American bullfrog tadpoles (Lithobates catesbeianus, Shaw, 1802) exposed to the herbicide Tebuthiuron.
Abel, G; Alves, TC; Bainy, ACD; Bitschinski, D; da Silva, EB; da Silva, SP; de Albuquerque, CAC; de Almeida, EA; Grott, SC; Israel, NG; Lima, D; Mattos, JJ, 2021
)
2.26

Toxicity

ExcerptReferenceRelevance
" However, the potential toxic effects of TBU on aquatic developing organisms have been poorly studied."( Integrating morphological, biochemical, behavioural, and molecular approaches to investigate developmental toxicity triggered by tebuthiuron in zebrafish (Danio rerio).
da Silva Ferreira, ME; de Oliveira, AÁS; Dorta, DJ; Dreossi, SC; Gravato, C; Oliveira, DP; Vieira, LC, 2023
)
1.12

Dosage Studied

ExcerptRelevanceReference
"Orally dosed tebuthiuron was readily absorbed in mice, rats, rabbits, dogs, and ducks."( Metabolism of a new herbicide, tebuthiuron (1-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- 1,3-dimethylurea), in mouse, rat, rabbit, dog, duck, and fish.
Hoffman, DG; Morton, DM, 1976
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
organosulfur heterocyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency707.94600.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159523
AR proteinHomo sapiens (human)Potency54.48270.000221.22318,912.5098AID743042
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.74580.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.57030.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.29930.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency86.43700.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency64.64560.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency46.06190.000229.305416,493.5996AID743075; AID743079; AID743080
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency1.94940.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency76.95880.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency76.95880.001628.015177.1139AID1224843
histone deacetylase 9 isoform 3Homo sapiens (human)Potency29.92310.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency76.95880.000627.21521,122.0200AID720636
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.57)18.7374
1990's1 (2.86)18.2507
2000's8 (22.86)29.6817
2010's14 (40.00)24.3611
2020's9 (25.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.83 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index5.58 (4.65)
Search Engine Demand Index79.83 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (32.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]